Study evaluates cost-effectiveness of olaparib for metastatic pancreatic cancer
Studies have shown that utilizing a PARP inhibitor in the management of patients with metastatic pancreatic cancer who harbor BRCA 1/2 mutations is clinically beneficial. New research in the November 2020 issue of JNCCN—Journal ...
Nov 12, 2020
0
1